PGNY · Progyny, Inc.

The thesis

Progyny's record selling season and raised 2026 outlook support further gains in the shares. The first 2027 guidance, expected with the fourth-quarter report around late February 2027, settles whether the new lives become revenue.

The 4 November 2026 report passed the test in the previous note. Third-quarter revenue was $341.3 million, up 8.9% and above the $335 million line, and the low end of full-year revenue guidance rose to $1.365 billion from $1.360 billion.

Progyny administers fertility and family-building benefits for self-insured employers, and it is rebuilding growth after losing a large client whose $48.5 million of 2025 transition revenue is absent from 2026. CEO Pete Anevski said in the 4 November 2026 release that the season produced 1.3 million new covered lives, "our most ever in a single season," with more than 85 new clients and retention near 100% for 2027. The company had expected 1.2 million on 7 October 2026.

The shares closed at $34.37 on 5 November 2026, the highest close in 52 weeks in adjusted daily closes. The narrative is accelerating: the 4 November 2026 report raised the selling-season count, and Leerink, Wells Fargo, Citizens and Cantor Fitzgerald all raised price targets on or around 5 November 2026. This read would be wrong on a daily close below $30, which would erase the post-earnings gain, or if the 1.3 million count is cut.

Bullish and bearish views on Progyny, Inc.

The bull case on Progyny, Inc. (PGNY), in brief: Largest selling season on record. The bear case: The revenue beat was thin.

Bull case

• Largest selling season on record. The 4 November 2026 release expects more than 660 clients and about 8.3 million covered lives once all new clients are live in 2027. Average members in the third quarter were 7,176,000, and clients numbered 607 on 30 September 2026.
• Profit outran revenue. Third-quarter gross profit rose to $83.7 million from $72.8 million, and gross margin reached 24.5% against 23.2%, per the 4 November 2026 release.
• Growth is faster without the departed client. The 4 November 2026 guidance puts full-year revenue growth at 5.9% to 7.5%, or 10.1% to 11.7% excluding the $48.5 million from the former client. Fourth-quarter revenue guidance of $344.7 million to $364.7 million implies growth of 8.3% to 14.6%, per the company.
• Buybacks are shrinking the share count. The company repurchased nearly 3 million shares for $82.7 million in the third quarter and 14.3 million since November 2025, per its 4 November 2026 slides. Guidance assumes 79.0 million diluted shares in the fourth quarter against 82.0 million for the full year.
• Analysts raised targets after the report. Citizens moved to $38 from $33, Leerink to $38 from $37, Wells Fargo to $38 from $37, and Cantor Fitzgerald to $35, per MarketBeat on 5 November 2026. BTIG's $40 target dates from 24 July 2026.

Bear case

• The revenue beat was thin. Third-quarter sales of $341.254 million compared with a $340.924 million estimate, per 4 November 2026 company news. The top of full-year guidance stayed at $1.385 billion, and the fourth-quarter range brackets the $353.596 million estimate.
• The headline EPS beat flatters the quarter. News headlines on 4 November 2026 set adjusted EPS of $0.52 against a $0.31 estimate. That estimate lines up with GAAP diluted EPS of $0.32, so the like-for-like beat looks narrow.
• Adjusted margin slipped. Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) rose 6.3% to $58.4 million, slower than revenue. The margin fell to 17.1% from 17.5%, per the 4 November 2026 release.
• Treatment volume lagged membership. Assisted reproductive technology cycles rose 4.6% to 16,723 in the third quarter, while average members rose 6.2%, per the 4 November 2026 slides.
• Buyback capacity is running down. About $51 million remains under the $200 million May 2026 program, and cash and marketable securities fell $41.3 million in the quarter to $195.6 million, per the release. The company has no debt and an undrawn $200 million revolving credit line.
• Small-employer pricing is still unmeasured. The Select product uses fixed premiums, and the question of whether they cover claims in smaller groups was raised around the 8 September 2026 coverage. The 4 November 2026 slides give no Select figures.

Price setup

The adjusted close was $34.37 on 5 November 2026, against $28.44 on 21 October 2026 and $25.44 on 25 September 2026. StockStory put the price just before the report at $30.10. MarketBeat showed the shares up $4.23, or 14.0%, at $34.33 during the 5 November 2026 session, narrower than the roughly 23% after-hours gain Chartmill reported.

Crowding is visible in momentum and in targets. The 14-day relative strength index (RSI), a gauge where readings above 70 mark a sharp short-term rise, stood at 83.3 on 5 November 2026. MarketBeat listed the 50-day moving average at $27.11 and the 200-day at $24.49, both well under the close. The shares rose 23.4% over three months in adjusted closes.

The $34.37 close sits just below MarketBeat's $34.92 average analyst target, which reflects 11 positive and 4 neutral ratings. MarketBeat's 52-week range tops out at $35.50, and it showed a price-to-earnings ratio of 37.31.

Insider selling was small and predates the report. The company retired shares in the quarter and issued none in a public offering, per its 4 November 2026 materials.

Catalysts, next 30 days

No company-announced event that decides the case falls in the next 30 days, per company releases through 6 November 2026.

• ~9 November 2026, est.: The third-quarter Form 10-Q filing deadline. It gives the next filed detail on repurchases and on risk disclosures.
• ~1 January 2027, est.: First launches of 2027 clients. The company says most new clients go live in the first quarter of 2027, with a meaningful number at mid-year.
• ~25 February 2027, est.: Fourth-quarter 2026 report and the first 2027 guidance. The date is unconfirmed, and the company's 4 November 2026 slides give no numeric 2027 outlook.
• 1 July 2027: The California Public Employees' Retirement System (CalPERS) effective date cited in Citizens' 8 September 2026 coverage. No revenue figure is attached to it, and the 4 November 2026 release does not name it.

What would change the view

The case breaks if the record season fails to reach revenue. That would show as a lower count than 1.3 million new lives, a lower figure than about 8.3 million covered lives, or first 2027 guidance that shows little lift from the new clients.

Current-year results could break it sooner. Fourth-quarter revenue below $344.7 million, or full-year revenue below $1.365 billion, would reverse the 4 November 2026 raise. Disclosed Select underwriting losses or further decline in adjusted EBITDA margin from 17.1% would weaken the profit side.

On price, a daily close below $30 ends the thesis. That level sits under the $30.10 pre-report price and would erase the post-earnings gain. It replaces the $24 weekly-close invalidation level in the previous note, because the report moved the reference point.

What it trades with

MarketBeat listed a beta of 0.97 on 5 November 2026, close to the market's own sensitivity. The largest recent move was company-specific: the 14.0% rise on 5 November 2026 followed the shares' own report and selling-season count.

Revenue depends on employer benefit decisions made in an annual selling cycle and on member treatment activity. The company's slides describe utilization as staying within a customary narrow range over the longer term, which ties results more to client and member counts than to short-term swings in demand.